 Connection
David Fox to Gene Expression Profiling
This is a "connection" page, showing publications David Fox has written about Gene Expression Profiling.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.118 |
|
|
|
-
Ikari Y, Lu C, Rosek A, Cai A, Khanna N, St Clair J, Webber A, Foster C, Chen YC, Ali RA, Khanna D, Fox DA, Tsou PS. Soluble CD13 in systemic sclerosis: clinical observations and transcriptomic insights from peripheral blood. Arthritis Res Ther. 2026 Jan 10; 28(1):30.
Score: 0.035
-
Li S, Liu Y, Zhang H, Xu S, Wen X, Tang Y, Zhang N, Fox DA, Chen Y, Pan Y, Lu C. Spatial transcriptomics uncovers lipid metabolic dysregulation driving immune-stroma crosstalk in Sjögren's Disease. EBioMedicine. 2026 Jan; 123:106074.
Score: 0.035
-
Wu Q, Mills EA, Wang Q, Dowling CA, Fisher C, Kirch B, Lundy SK, Fox DA, Mao-Draayer Y. Siponimod enriches regulatory T and B lymphocytes in secondary progressive multiple sclerosis. JCI Insight. 2020 02 13; 5(3).
Score: 0.024
-
Khanna D, Spino C, Johnson S, Chung L, Whitfield ML, Denton CP, Berrocal V, Franks J, Mehta B, Molitor J, Steen VD, Lafyatis R, Simms RW, Gill A, Kafaja S, Frech TM, Hsu V, Domsic RT, Pope JE, Gordon JK, Mayes MD, Schiopu E, Young A, Sandorfi N, Park J, Hant FN, Bernstein EJ, Chatterjee S, Castelino FV, Ajam A, Wang Y, Wood T, Allanore Y, Matucci-Cerinic M, Distler O, Singer O, Bush E, Fox DA, Furst DE. Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. Arthritis Rheumatol. 2020 01; 72(1):125-136.
Score: 0.023
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|